Drugs / CPL207280
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04622111 | May 2020 → Apr 2021 | — | Celon Pharma SA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05248776 | Jan 2022 → Jun 2023 | type 2 diabetes mellitus | Celon Pharma SA | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPL207280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622111 ↗ |
| Action | Activate | “CPL207280 (GPR40 Agonist)” NCT05248776 ↗ |
| Route | Oral | “different doses of IMP administered orally for two weeks in PART B” NCT04622111 ↗ |